tradingkey.logo

Johnson & Johnson falls after talc litigation overshadows 2026 profit forecast

ReutersJan 21, 2026 4:48 PM

Shares of healthcare conglomerate Johnson & Johnson JNJ.N fall 1.9% to $214.13

On Tuesday, a court-appointed special master recommended that expert testimony linking the company's talc products to ovarian cancer be allowed in court

J&J has been fighting claims over its talc products in both federal and state court for years, but it has maintained that its products are safe and do not cause cancer

"The talc litigation concerns may be driving the stock down slightly in pre-market trading," RBC Capital Markets analysts wrote in a note

Co forecasts 2026 adj. profit in the range of $11.43 and $11.63 per share, above analysts' estimate of $11.45 per share, according to data compiled by LSEG

JNJ posts Q4 adj. profit of $2.46 per share, compared with analysts' estimate of $2.44 per share

Reports Q4 revenue of $24.56 billion, beating estimates of $24.16 billion

JNJ stock climbed 43.1% in 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI